Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT04343586 Completed - Psoriasis Vulgaris Clinical Trials

Blue Light Phototherapy

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and Grover's Disease.

NCT ID: NCT04316585 Completed - Psoriasis Clinical Trials

A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants

Start date: September 28, 2020
Phase: Phase 1
Study type: Interventional

Plaque psoriasis is a chronic relapsing inflammatory skin disease that is characterized by keratinocyte hyper-proliferation and epidermal hyperplasia. Standard treatment for psoriasis generally requires long-term use of topical therapies, psoralen and ultraviolet A (PUVA), ultraviolet B (UVB) and/or systemic immunosuppressant therapies to achieve and maintain adequate disease control. This is a multicenter, randomized, double-blind study conducted in participants with moderate to severe plaque psoriasis. The study will evaluate the efficacy, safety, pharmacokinetic and pharmacodynamics profile of 960 milligram (mg) GSK2982772 administered as a once daily modified release (MR) formulation. Participants will be randomized in a 2:1 ratio to receive either 960 mg GSK2982772 or placebo for 12 weeks. The duration of the study, including Screening and follow-up, will be approximately 21 weeks for each participant.

NCT ID: NCT04316533 Completed - Psoriasis Clinical Trials

Work Stress and Impact of Pruritus on Quality of Life

PRUERI
Start date: March 9, 2020
Phase:
Study type: Observational

Work stress and pruritus: imbalance of effort balance reward in patients with psoriasis.

NCT ID: NCT04308616 Completed - Psoriasis Clinical Trials

Utility of Squamous Cell Carcinoma Antigen (SCCA) in Psoriasis

SCCAPSO
Start date: July 20, 2020
Phase:
Study type: Observational

Squamous Cell Carcinoma Antigen (SCCA) contributes to the pathogenesis of psoriasis by inhibiting cell apoptosis, exacerbating epidermal hyperplasia and skin inflammation. Three studies have shown a correlation between blood levels of SCCA and the severity of psoriasis. Clinical scores of psoriasis severity are used in consultation to guide treatment of the disease (initiation of systemic therapy, dose escalation) but they suffer from several pitfalls: lack of inter- and intra-observer reproducibility, consumption of medical time. A readily available, inexpensive (24 euros) blood marker could be an interesting alternative to these clinical scores.

NCT ID: NCT04286607 Completed - Clinical trials for Chronic Plaque Psoriasis

Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

DERMIS-OLE
Start date: February 12, 2020
Phase: Phase 3
Study type: Interventional

This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis

NCT ID: NCT04279119 Completed - Plaque Psoriasis Clinical Trials

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis

MUSE
Start date: March 10, 2020
Phase: Phase 1
Study type: Interventional

This is a phase 1, open label, single arm study in which ARQ-151 cream 0.3% is applied QD for 2 weeks to adolescent subjects with chronic plaque psoriasis involving at least 10% body surface area (BSA) and adult subjects with chronic plaque psoriasis involving at least 20% BSA (excluding scalp). The objectives of this study are to evaluate the exposure and characterize the plasma pharmacokinetic profile and to assess the safety and tolerability of ARQ-151 cream 0.3% administered once daily for 2 weeks to adolescent and adult subjects with chronic plaque psoriasis.

NCT ID: NCT04277832 Completed - Psoriasis Clinical Trials

Evaluating of New Screening Tool for Arthritis* in Psoriasis

TUPAST
Start date: February 21, 2020
Phase:
Study type: Observational

This study evaluates a new screening tool for arthritis in psoriasis and compares its reliability with well-known screening tool (TOPAS 2).

NCT ID: NCT04275024 Completed - Psoriasis Clinical Trials

Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients

Start date: April 1, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Adipose derived Mesenchymal Stem Cells (AD-MSCs) plus Calpocitriol Ointment and PSORI-CM01 Granule with moderate to severe psoriasis. Any adverse events related to AD-MSCs infusion will be monitored.The primary outcome is the reduction rate of PASI(Psoriasis Area and Severity Index) and treatment response will be computed from PASI before and after treatment.

NCT ID: NCT04274595 Completed - Psoriasis Clinical Trials

Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis

PSORTI-BIO
Start date: February 13, 2020
Phase: N/A
Study type: Interventional

The investigators hypothesize that the inhibition of endogenous reverse transcriptase would: (1) reduce excess cytosolic DNA, stress initiating the inflammatory loop at the origin of psoriatic lesions, and (2) interrupt the loop and lighten lesions

NCT ID: NCT04271735 Completed - Obesity Clinical Trials

Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis

Start date: August 26, 2020
Phase: N/A
Study type: Interventional

Background: Psoriasis causes chronic inflammation in the body. Researchers want to see if a kind of vitamin B3 dietary supplement can help. This might lead to more treatment options. Objective: To test if the dietary supplement nicotinamide riboside can improve immune system function in the blood and skin of people with mild to moderate psoriasis. Eligibility: People ages 18-80 with mild to moderate active psoriasis not currently treated with biological therapy Design: Participations will be screened with: - Medical and medication history - Physical exam - Measure of body mass index - Skin exam - Blood and urine tests Participants will have visit 1. They will have repeats of the screening tests. They may also have 2 skin biopsies, which are optional. These will be from both lesions and unaffected areas. The areas will be injected with a numbing medicine. A round cutting device will remove small pieces of skin from each area. Participants will take the study supplement or a placebo starting at the first visit. Neither participants nor the study team will know which they receive. Participants will take capsules twice daily for a total of 4 weeks. Participants will then have visit 2. This will include the tests performed at visit 1. Participants may by contacted by phone or email between visits to see how they are doing. If participants develop any side effects in the 7 days after they stop taking the capsules, they may have another visit.